This technology is an antibody-based platform that binds transmembrane protein 106B (TMEM106B) amyloid aggregates to diagnose and treat neurodegenerative diseases.
Protein aggregation is a hallmark of many neurogenerative diseases, yet current diagnostic and therapeutic strategies rely largely on nonspecific biomarkers, post-mortem pathology, or treatments that do not directly address aggregation-driven disease progression. As a result, there is a critical lack of tools capable of selectively recognizing pathogenic protein aggregates across these diseases, limiting accurate diagnosis and therapeutic effectiveness.
This technology is an IgG and IgM-based antibody platform that selectively binds to the C-terminal fragment of transmembrane protein 106B (TMEM106B) aggregates. TMEM106B forms amyloid fibrils in multiple neurodegenerative diseases, enabling these antibodies to selectively recognize aggregation states associated with neurodegenerative pathology.
Anthony William Paul Fitzpatrick, Ph.D.
Patent Pending (WO/2025/117530)
IR CU23354
Licensing Contact: Kristin Neuman